» Articles » PMID: 27455234

Matrix Metalloproteinases in Non-Neoplastic Disorders

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2016 Jul 26
PMID 27455234
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

The matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases belonging to the metzincin superfamily. There are at least 23 members of MMPs ever reported in human, and they and their substrates are widely expressed in many tissues. Recent growing evidence has established that MMP not only can degrade a variety of components of extracellular matrix, but also can cleave and activate various non-matrix proteins, including cytokines, chemokines and growth factors, contributing to both physiological and pathological processes. In normal conditions, MMP expression and activity are tightly regulated via interactions between their activators and inhibitors. Imbalance among these factors, however, results in dysregulated MMP activity, which causes tissue destruction and functional alteration or local inflammation, leading to the development of diverse diseases, such as cardiovascular disease, arthritis, neurodegenerative disease, as well as cancer. This article focuses on the accumulated evidence supporting a wide range of roles of MMPs in various non-neoplastic diseases and provides an outlook on the therapeutic potential of inhibiting MMP action.

Citing Articles

Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma.

Yildiz F, Sahinoglu-Keskek N, Yilmaz I, Candan I, Korkmaz O J Curr Ophthalmol. 2025; 36(2):136-144.

PMID: 40012807 PMC: 11856119. DOI: 10.4103/joco.joco_290_23.


Integrated Bioinformatics-Based Identification and Validation of Neuroinflammation-Related Hub Genes in Primary Open-Angle Glaucoma.

Ullah Z, Tao Y, Huang J Int J Mol Sci. 2024; 25(15).

PMID: 39125762 PMC: 11311784. DOI: 10.3390/ijms25158193.


Tumor biomarkers for diagnosis, prognosis and targeted therapy.

Zhou Y, Tao L, Qiu J, Xu J, Yang X, Zhang Y Signal Transduct Target Ther. 2024; 9(1):132.

PMID: 38763973 PMC: 11102923. DOI: 10.1038/s41392-024-01823-2.


Metalloproteinases as Biomarkers and Sociomarkers in Human Health and Disease.

Costa D, Scalise E, Ielapi N, Bracale U, Andreucci M, Serra R Biomolecules. 2024; 14(1).

PMID: 38254696 PMC: 10813678. DOI: 10.3390/biom14010096.


Novel Matrix Metalloproteinase-9 (MMP-9) Inhibitors in Cancer Treatment.

Rashid Z, Bardaweel S Int J Mol Sci. 2023; 24(15).

PMID: 37569509 PMC: 10418771. DOI: 10.3390/ijms241512133.


References
1.
Tocchi A, Parks W . Functional interactions between matrix metalloproteinases and glycosaminoglycans. FEBS J. 2013; 280(10):2332-41. DOI: 10.1111/febs.12198. View

2.
Murphy G . The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer. 2008; 8(12):929-41. DOI: 10.1038/nrc2459. View

3.
Kunugi S, Shimizu A, Kuwahara N, Du X, Takahashi M, Terasaki Y . Inhibition of matrix metalloproteinases reduces ischemia-reperfusion acute kidney injury. Lab Invest. 2010; 91(2):170-80. DOI: 10.1038/labinvest.2010.174. View

4.
Xu J, Rodriguez D, Petitclerc E, Kim J, Hangai M, Moon Y . Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol. 2001; 154(5):1069-79. PMC: 2196184. DOI: 10.1083/jcb.200103111. View

5.
DArmiento J, Dalal S, Okada Y, Berg R, Chada K . Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema. Cell. 1992; 71(6):955-61. DOI: 10.1016/0092-8674(92)90391-o. View